



## New Diagnostic and Therapeutic Aspects of Thrombotic Thrombocytopenic Purpura

Guest Editors:

**Dr. Ilaria Mancini**

Department of Pathophysiology  
and Transplantation, and  
Fondazione Luigi Villa, Università  
degli Studi di Milano, 20122  
Milan, Italy

**Dr. Andrea Artoni**

Fondazione IRCCS Ca' Granda  
Ospedale Maggiore Policlinico,  
Angelo Bianchi Bonomi  
Hemophilia and Thrombosis  
Center, 20122 Milan, Italy

Deadline for manuscript  
submissions:

**closed (20 June 2023)**

### Message from the Guest Editors

Dear Colleagues,

Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy caused by the congenital or acquired severe deficiency of the von Willebrand factor cleaving protease, ADAMTS13. Acute TTP is a medical emergency requiring a fast differential diagnosis and immediate treatment, which is often challenging due to the overlap of clinical and laboratory features with other thrombotic microangiopathies. Diagnostic and therapeutic advancements in the last decade, including the increased availability of ADAMTS13 testing and the development of caplacizumab, the first targeted therapy for acquired TTP, have significantly improved the management of acute TTP and reduced the burden of such short-term outcomes as mortality and exacerbation of acute disease. At the same time, new clinical challenges have emerged, to mention one addressing the burden of long-term complications of TTP and cardiovascular comorbidities in TTP patients in remission.

This Special Issue will cover new diagnostic and therapeutic aspects of TTP care, with the scope of advancing our knowledge and clinical intervention to address the current challenges of TTP management.





an Open Access Journal by MDPI

## Editors-in-Chief

**Prof. Dr. Emmanuel Andrès**

Internal Medicine Department,  
University Hospital Strasbourg,  
67000 Strasbourg, France

**Prof. Dr. Kent Doi**

Department of Acute Care  
Medicine, University of Tokyo,  
Tokyo, Japan

## Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) / CiteScore - Q1 (*General Medicine*)

## Contact Us

*Journal of Clinical Medicine* Editorial  
Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jcm](http://mdpi.com/journal/jcm)  
[jcm@mdpi.com](mailto:jcm@mdpi.com)  
[X@JCM\\_MDPI](https://twitter.com/JCM_MDPI)